Clinical Trial Update: Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sofobuvir/velpatasvir with ribavirin for 12 weeks in chronic HCV with Child-Pugh C cirrhosis; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Disease

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2019-10-08